CoChat

A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities

Open access
Park, Woo-Jung, Kim, Moon Jong · 2023 · Cells

The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.

Abstract

Aberrant Wnt signaling activation is frequently observed in many cancers. The mutation acquisition of Wnt signaling leads to tumorigenesis, whereas the inhibition of Wnt signaling robustly suppresses tumor development in various in vivo models. Based on the excellent preclinical effect of targeting Wnt signaling, over the past 40 years, numerous Wnt-targeted therapies have been investigated for cancer treatment. However, Wnt signaling-targeting drugs are still not clinically available. A major obstacle to Wnt targeting is the concomitant side effects during treatment due to the pleiotropic role of Wnt signaling in development, tissue homeostasis, and stem cells. Additionally, the complexity of the Wnt signaling cascades across different cancer contexts hinders the development of optimized targeted therapies. Although the therapeutic targeting of Wnt signaling remains challenging, alternative strategies have been continuously developed alongside technological advances. In this review, we give an overview of current Wnt targeting strategies and discuss recent promising trials that have the potential to be clinically realized based on their mechanism of action. Furthermore, we highlight new waves of Wnt targeting that combine recently developed technologies such as PROTAC/molecular glue, antibody–drug conjugates (ADC), and anti-sense oligonucleotides (ASO), which may provide us with new opportunities to target ‘undruggable’ Wnt signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells12081110

Cites

188 of 188 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Wnt signaling and its alteration in various cancers. Signal transduction of β-catenin-dependent and independent Wnt signaling. The frequencies of genetic alteration of individual Wnt signaling modules in indicated cancers were summarized.
Figure 1 Wnt signaling and its alteration in various cancers. Signal transduction of β-catenin-dependent and independent Wnt signaling. The frequencies of genetic alteration of individual Wnt signaling modules in indicated cancers were summarized.CC BY · PubMed Central
Figure 2 Wnt signaling modulating agents in clinical trials for cancer treatment. Promising clinical agents targeting the Wnt signaling module were displayed along with their targets.
Figure 2 Wnt signaling modulating agents in clinical trials for cancer treatment. Promising clinical agents targeting the Wnt signaling module were displayed along with their targets.CC BY · PubMed Central
Figure 3 Targeting Wnt signaling pathway by the latest technologies. β-catenin targeted PROTACs (xStAx-VHL) recruits E3 ligase to β-catenin, inducing the degradation of β-catenin using the ubiquitin–proteasome system. Additionally, the molecular glue of β-catenin and its E3 ligase β-TrCP, NRX-252114, enhances the β-catenin degradation. ADCs (LGR5-mc-vc-PAB-MMAE, LRG5-NMs818, and PF-06647020) targeting LGR5- or PTK7-expressing Wnt responder cells bind to the target cells and release a cytotoxic drug to induce the cell death. ASO (LNA-modified ASO, β-catenin targeting ASO) binds to the target region of RNA and suppresses expression.
Figure 3 Targeting Wnt signaling pathway by the latest technologies. β-catenin targeted PROTACs (xStAx-VHL) recruits E3 ligase to β-catenin, inducing the degradation of β-catenin using the ubiquitin–proteasome system. Additionally, the molecular glue of β-catenin and its E3 ligase β-TrCP, NRX-252114, enhances the β-catenin degradation. ADCs (LGR5-mc-vc-PAB-MMAE, LRG5-NMs818, and PF-06647020) targeting LGR5- or PTK7-expressing Wnt responder cells bind to the target cells and release a cytotoxic drug to induce the cell death. ASO (LNA-modified ASO, β-catenin targeting ASO) binds to the target region of RNA and suppresses expression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 188 references

Cited by

See all 58

Metadata

Authors
Park, W.-J., & Kim, M. J.
Affiliations
Gachon University (KR)
Corresponding author
Kim, Moon Jong
Venue
Cells
Publisher
MDPI AG
Published
2023-04-08
Volume
12
Issue
8
Pages
1110
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4363648015
Cited by
57
References
188
Citations by year
2026: 18 · 2025: 13 · 2024: 20 · 2023: 6
FWCI
1.51
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Gachon University (GCU-202110420001, NRF-2022R1F1A1074582)
  • Korean government (MSIT) (GCU-202110420001, NRF-2022R1F1A1074582)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
Wnt signaling, undruggable targets, cancer therapy, Wnt inhibitors, PROTACs, molecular glues, antibody-drug conjugates, antisense oligonucleotides, clinical trials
MeSH terms
Cell Transformation, Neoplastic, Humans, Neoplasms, Stem Cells, Wnt Signaling Pathway, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. https://app.cochat.ai/papers/10.3390/cells12081110
The paper
Park, W.-J., & Kim, M. J. (2023). A New Wave of Targeting ‘Undruggable’ Wnt Signaling for Cancer Therapy: Challenges and Opportunities. Cells. https://doi.org/10.3390/cells12081110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.